Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Obesity

Donald Trump Rule: Age, Obesity, Diabetes Trigger US Visa Ban on Public Charge

The Trump administration issued a new directive allowing US visa officers to reject applicants based on obesity, diabetes, and age. The policy flags immigrants as a potential 'public charge.'

International Business Times UK

The nut secret: 14 easy, delicious ways to eat more of these life-changing superfoods

A handful of nuts a day can help manage obesity and reduce your risk of cardiovascular disease, type 2 diabetes and some kinds of cancer. Yet most of us don’t get enough. Here’s a no-fuss guide to getting your 30g a day

The Guardian - UK

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Fact check: Fake ‘train attack’ imagery and child obesity stats

Round-up of fact checks from the last week compiled by Full Fact.

Evening Standard

On the same day as his ‘fat jab’ launch, Trump issued new reason to deny visas to foreigners: obesity

The guidance describes obese foreigners as a ‘public charge’ and orders visa officers to guess how much they would claim in benefits

The Independent UK

‘Dozy Don’ allegations reappear after president closes eyes during Dr. Oz speech

President photographed appearing to doze during announcement of price cuts for weight loss drugs – which tackle obesity and aid sleep

The Independent UK

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included

On Thursday, the U.S. Food and Drug Administration (FDA) announced six additional awardees under the Commissioner's National Priority Voucher (CNPV) pilot program.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

TrumpRx News: Why Donald Trump Struck a Deal With Novo Nordisk's Weight Loss Drugs — And What It Says About America's Obesity Problem

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current average retail price of $1,000–$1,350.

International Business Times UK

Childhood obesity reaching ‘alarmingly high’ levels in Europe, WHO report warns

Child obesity rates have stabilised in some countries in recent years – but global health officials said they were still too high.

Euronews

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

Benzinga

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx

President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs.

Benzinga

Trump announces plans to slim down cost of popular weight-loss drugs to $149 a month

Novo Nordisk and Eli Lilly become latest drug companies to bend knee to Trump’s ‘most-favored nation’ pricing plan

The Independent UK

Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy

The Independent UK

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits

At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

This is the exercise you need to combat obesity and diabetes, new study says

It’s estimated that more than 5.8 million people in the UK are living with diabetes, which is an all-time high, according to Diabetes UK

Benzinga

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk A/S (NASDAQ:NVO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. NVO is having a challenging session. See if it is worth your attention here. This transcript is brought to you by Benzinga APIs. For real-time access to our entire…

Evening Standard

Novo Nordisk cuts sales and profits guidance amid obesity drug competition

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.

International Business Times

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion.

The Independent UK

New food warnings could save thousands of peoples’ lives, experts say

Many countries have brought in a mandatory nutritional warning label law

Evening Standard

More than 100,000 obesity deaths ‘could be prevented with new food warnings’

Mandatory nutrient warning labels could deliver substantial health benefits for the population, experts said.

The Independent UK

Trump team is negotiating with weight-loss drug makers to lower prices to $149 a month: report

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that purpose

Benzinga

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.

Evening Standard

Child obesity crisis: London has worst record in weight surge for primary school youngsters, report reveals

More than a fifth of Year Six pupils in the capital are obese, according to new study

The Independent UK

Mapped: The areas where almost one in three children are obese

The figures were called ‘extremely concerning’ by the NHS national clinical director for children and young people

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.